Literature DB >> 28560406

Silencing of ATM expression by siRNA technique contributes to glioma stem cell radiosensitivity in vitro and in vivo.

Yan Li1, Luchun Li1, Zhijuan Wu1, Lulu Wang1, Yongzhong Wu2, Dairong Li1, Uiwen Ma1, Jianghe Shao1, Huiqing Yu1, Donglin Wang1.   

Abstract

Evidence has shown that both high expression of the ataxia-telangiectasia mutated (ATM) gene and glioma stem cells (GSCs) are responsible for radioresistance in glioma. Thus, we hypothesized that brain tumor radiosensitivity may be enhanced via silencing of the ATM gene in GSCs. In the present study we successfully induced GSCs from two cell lines and used CD133 and nestin to identify GSCs. A lentivirus was used to deliver siRNA-ATMPuro (A group) to GSCs prior to radiation, while siRNA-HKPuro (N group) and GSCs (C group) were used as negative and blank controls, respectively. RT-qPCR and western blotting were performed to verify the efficiency of the siRNA-ATM technique. The expression of the ATM gene and ATM protein were significantly downregulated post-transfection. Cell Counting Kit-8 (CCK-8) and colony formation assays revealed that the A group demonstrated weak cell proliferation and lower survival fractions post-irradiation compared to the C/N groups. Flow cytometry was used to examine the percentage of cell apoptosis and G2 phase arrest, which were both higher in the A group than in the C/N groups. We found that the comet tail percentage evaluated by comet assay was higher in the A group than in the C/N groups. After radiation treatment, three radiosensitive genes [p53, proliferating cell nuclear antigen (PCNA), survivin] exhibited a decreasing tendency as determined by RT-qPCR. Mice underwent subcutaneous implantation, followed by radiation, and the resulting necrosis and hemorrhage were more obvious in the A group than in the N groups. In conclusion, silencing of ATM via the siRNA technique improved radiosensitivity of GSCs both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28560406     DOI: 10.3892/or.2017.5665

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

Review 1.  Macrotrabecular-Massive Hepatocellular Carcinoma: What Should We Know?

Authors:  Xiaoming Li; Qiandong Yao; Chen Liu; Jian Wang; Huarong Zhang; Shiguang Li; Ping Cai
Journal:  J Hepatocell Carcinoma       Date:  2022-05-05

2.  Loss of GINS2 inhibits cell proliferation and tumorigenesis in human gliomas.

Authors:  Yun-Long Shen; He-Zhen Li; Yan-Wei Hu; Lei Zheng; Qian Wang
Journal:  CNS Neurosci Ther       Date:  2018-10-18       Impact factor: 5.243

3.  ATM in breast and brain tumors: a comprehensive review.

Authors:  Mehrdad Asghari Estiar; Parvin Mehdipour
Journal:  Cancer Biol Med       Date:  2018-08       Impact factor: 4.248

Review 4.  Targeting Cell Cycle Checkpoint Kinases to Overcome Intrinsic Radioresistance in Brain Tumor Cells.

Authors:  Tijana Vlatkovic; Marlon R Veldwijk; Frank A Giordano; Carsten Herskind
Journal:  Cancers (Basel)       Date:  2022-01-29       Impact factor: 6.639

5.  Liposomal delivery of ferritin heavy chain 1 (FTH1) siRNA in patient xenograft derived glioblastoma initiating cells suggests different sensitivities to radiation and distinct survival mechanisms.

Authors:  Vagisha Ravi; Achuthamangalam B Madhankumar; Thomas Abraham; Becky Slagle-Webb; James R Connor
Journal:  PLoS One       Date:  2019-09-06       Impact factor: 3.240

6.  Methylation of the ataxia telangiectasia mutated gene (ATM) promoter as a radiotherapy outcome biomarker in patients with hepatocellular carcinoma.

Authors:  Xinjian Yan; Tianyu Wu; Mei Tang; Dongliang Chen; Meiyuan Huang; Sichun Zhou; Huihui Zhang; Xiaoping Yang; Gaofeng Li
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

7.  Targeting survivin sensitizes cervical cancer cells to radiation treatment.

Authors:  Jing Zhou; Xiaojing Guo; Weifen Chen; Liming Wang; Yonglong Jin
Journal:  Bioengineered       Date:  2020-12       Impact factor: 3.269

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.